Journal Article

Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

Anisoglou, Souzana, Karakike, Eleni, Schrijver, Irene T., Frantzeskaki, Frantzeska, Massa, Eleni, Pitsoulis, Achillefs, Antoniadou, Anastasia, Scicluna, Brendon P., Karampela, Niki, Antoniadou, Eleni, Vlachogianni, Glykeria, Psaroulis, Konstantinos, Mitrou, Ioannis, Floros, Ioannis, Wiersinga, W. Joost, De Bels, David, Giamarellos-Bourboulis, Evangelos J., Lada, Malvina, Patrani, Maria, Roumpoutsou, Maria, Dauby, Nicolas, Grimaldi, David, Roger, Thierry, Karageorgos, Athanasios, Tsangaris, Iraklis, Pappa, Evanthia, Mouloudi, Eleni, Chaloulis, Panagiotis

2022

Overview

Background Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive. We aimed to evaluate whether clarithromycin improves 28-day mortality among patients with sepsis, respiratory and multiple organ dysfunction syndrome. Methods We conducted a multicenter, randomized, clinical trial in patients with sepsis. Participants with ratio of partial oxygen pressure to fraction of inspired oxygen less than 200 and more than 3 SOFA points from systems other than the respiratory function were enrolled between December 2017 and September 2019. Patients were randomized to receive 1 gr of clarithromycin or placebo intravenously once daily for 4 consecutive days. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 90-day mortality; sepsis response (defined as at least 25% decrease in SOFA score by day 7); sepsis recurrence; and differences in peripheral blood cell populations and leukocyte transcriptomics. Results Fifty-five patients were allocated to each arm. By day 28, 27 (49.1%) patients in the clarithromycin and 25 (45.5%) in the placebo group died (risk difference 3.6% [95% confidence interval (CI) − 15.7 to 22.7]; P  = 0.703, adjusted OR 1.03 [95%CI 0.35–3.06]; P  = 0.959). There were no statistical differences in 90-day mortality and sepsis response. Clarithromycin was associated with lower incidence of sepsis recurrence (OR 0.21 [95%CI 0.06–0.68]; P  = 0.012); significant increase in monocyte HLA-DR expression; expansion of non-classical monocytes; and upregulation of genes involved in cholesterol homeostasis. Serious and non-serious adverse events were equally distributed. Conclusions Clarithromycin did not reduce mortality among patients with sepsis with respiratory and multiple organ dysfunction. Clarithromycin was associated with lower sepsis recurrence, possibly through a mechanism of immune restoration. Clinical trial registration clinicaltrials.gov identifier NCT03345992 registered 17 November 2017; EudraCT 2017-001056-55.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Antibiotics / Blood / Cholesterol / Clarithromycin / Clinical trials / Comorbidity / Consent / Critical care / Critical Care Medicine / Drug dosages / Emergency Medicine / Ethics / Gene expression / Hospitals / Infections / Intensive / Macrolides / Medicine / Medicine & Public Health / Mortality / Multiple organ dysfunction / Multiple organ dysfunction syndrome / Patients / Pneumonia / Recurrence / Regression analysis / Sepsis / Statistical analysis